Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury
CompletedPhase 1, Phase 2NCT04379011
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Spinal cord injury (SCI) is associated with severe neuropathic pain that is often refractory to all pharmacological intervention. Preliminary data suggest brivarecetum is a mechanism-based pharmacological intervention for neuropathic pain in SCI. This randomized, placebo-controlled pilot clinical trial will assess feasibility of a 3-month treatment course with brivarecetum.
Study details
- Official title
- Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Pilot Clinical Trial
- Conditions
- Interventions
- Drug: Brivaracetam
- Other: Placebo
- Sponsor
- University of Minnesota
- Start date
- 2021-02-01
- Primary completion
- 2024-03-31
- Sex
- All
- Age range
- from 18 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 2
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Spinal cord injury (SCI) * Participants must have completed inpatient rehabilitation and are living in the community * Participant who have severe below-level neuropathic pain (daily average 9/10 or 10/10) * Participants must have tried and failed to achieve adequate pain relief with the use of other drugs (i.e treatment failed to decrease their pain below a level of 9) and can continue to take spasmolytics, pregabalin, gabapentin, and opioids in unchanged dosing throughout the trial Exclusion Criteria: * Pprogressive myelopathy secondary to posttraumatic cord tethering * Syringomyelia * Brain injury limiting the ability to follow directions * Pregnancy or lactation * Epilepsy * Impaired liver or renal function * Contraindications to brivaracetam or pyrrolidine derivatives including allergy, or contraindications to MRI including retained bullet fragments, noncompatible metal implants, and implanted devices such as baclofen pumps
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04379011